PMC:7278327 / 5174-5949 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T31","span":{"begin":128,"end":131},"obj":"Body_part"},{"id":"T32","span":{"begin":357,"end":362},"obj":"Body_part"},{"id":"T33","span":{"begin":363,"end":368},"obj":"Body_part"},{"id":"T34","span":{"begin":448,"end":451},"obj":"Body_part"},{"id":"T35","span":{"begin":639,"end":647},"obj":"Body_part"},{"id":"T36","span":{"begin":691,"end":694},"obj":"Body_part"}],"attributes":[{"id":"A31","pred":"fma_id","subj":"T31","obj":"http://purl.org/sig/ont/fma/fma55675"},{"id":"A32","pred":"fma_id","subj":"T32","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A33","pred":"fma_id","subj":"T33","obj":"http://purl.org/sig/ont/fma/fma50801"},{"id":"A34","pred":"fma_id","subj":"T34","obj":"http://purl.org/sig/ont/fma/fma55675"},{"id":"A35","pred":"fma_id","subj":"T35","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A36","pred":"fma_id","subj":"T36","obj":"http://purl.org/sig/ont/fma/fma278683"}],"text":"Several empirical studies have demonstrated that the nAChR represents a major receptor for the RABV that mechanistically drives CNS transport of infective viral particles, leading to classic neurological sequelae associated with disease progression [15–17]. Due to the efficient neuroinvasive properties of RABV [18,19], including the ability to bypass the blood-brain barrier, studies have used RABV-based vectors for the delivery of drugs to the CNS, with some success [20]. Furthermore, genetic engineering of the RABV has been employed to generate novel vaccines consisting of non-replicating RABV particles expressing chimeric capsid proteins containing human immunodeficiency virus 1 (HIV-1) [21,22], MERS-CoV, Ebolavirus, and hepatitis C virus (HCV) sequences [23–25]."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T10","span":{"begin":357,"end":376},"obj":"Body_part"},{"id":"T11","span":{"begin":357,"end":362},"obj":"Body_part"},{"id":"T12","span":{"begin":363,"end":368},"obj":"Body_part"}],"attributes":[{"id":"A10","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0000120"},{"id":"A11","pred":"uberon_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A12","pred":"uberon_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/UBERON_0000955"}],"text":"Several empirical studies have demonstrated that the nAChR represents a major receptor for the RABV that mechanistically drives CNS transport of infective viral particles, leading to classic neurological sequelae associated with disease progression [15–17]. Due to the efficient neuroinvasive properties of RABV [18,19], including the ability to bypass the blood-brain barrier, studies have used RABV-based vectors for the delivery of drugs to the CNS, with some success [20]. Furthermore, genetic engineering of the RABV has been employed to generate novel vaccines consisting of non-replicating RABV particles expressing chimeric capsid proteins containing human immunodeficiency virus 1 (HIV-1) [21,22], MERS-CoV, Ebolavirus, and hepatitis C virus (HCV) sequences [23–25]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"183","span":{"begin":53,"end":58},"obj":"Gene"},{"id":"184","span":{"begin":659,"end":689},"obj":"Species"},{"id":"185","span":{"begin":691,"end":696},"obj":"Species"},{"id":"186","span":{"begin":707,"end":715},"obj":"Species"},{"id":"187","span":{"begin":733,"end":750},"obj":"Species"},{"id":"188","span":{"begin":95,"end":99},"obj":"Species"},{"id":"189","span":{"begin":307,"end":311},"obj":"Species"},{"id":"190","span":{"begin":396,"end":400},"obj":"Species"},{"id":"191","span":{"begin":517,"end":521},"obj":"Species"},{"id":"192","span":{"begin":597,"end":601},"obj":"Species"},{"id":"193","span":{"begin":752,"end":755},"obj":"Species"}],"attributes":[{"id":"A183","pred":"tao:has_database_id","subj":"183","obj":"Gene:1137"},{"id":"A184","pred":"tao:has_database_id","subj":"184","obj":"Tax:11676"},{"id":"A185","pred":"tao:has_database_id","subj":"185","obj":"Tax:11676"},{"id":"A186","pred":"tao:has_database_id","subj":"186","obj":"Tax:1335626"},{"id":"A187","pred":"tao:has_database_id","subj":"187","obj":"Tax:11103"},{"id":"A188","pred":"tao:has_database_id","subj":"188","obj":"Tax:11292"},{"id":"A189","pred":"tao:has_database_id","subj":"189","obj":"Tax:11292"},{"id":"A190","pred":"tao:has_database_id","subj":"190","obj":"Tax:11292"},{"id":"A191","pred":"tao:has_database_id","subj":"191","obj":"Tax:11292"},{"id":"A192","pred":"tao:has_database_id","subj":"192","obj":"Tax:11292"},{"id":"A193","pred":"tao:has_database_id","subj":"193","obj":"Tax:11103"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Several empirical studies have demonstrated that the nAChR represents a major receptor for the RABV that mechanistically drives CNS transport of infective viral particles, leading to classic neurological sequelae associated with disease progression [15–17]. Due to the efficient neuroinvasive properties of RABV [18,19], including the ability to bypass the blood-brain barrier, studies have used RABV-based vectors for the delivery of drugs to the CNS, with some success [20]. Furthermore, genetic engineering of the RABV has been employed to generate novel vaccines consisting of non-replicating RABV particles expressing chimeric capsid proteins containing human immunodeficiency virus 1 (HIV-1) [21,22], MERS-CoV, Ebolavirus, and hepatitis C virus (HCV) sequences [23–25]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T54","span":{"begin":665,"end":681},"obj":"Disease"},{"id":"T55","span":{"begin":733,"end":744},"obj":"Disease"},{"id":"T56","span":{"begin":733,"end":742},"obj":"Disease"}],"attributes":[{"id":"A54","pred":"mondo_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/MONDO_0021094"},{"id":"A55","pred":"mondo_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/MONDO_0005231"},{"id":"A56","pred":"mondo_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/MONDO_0002251"}],"text":"Several empirical studies have demonstrated that the nAChR represents a major receptor for the RABV that mechanistically drives CNS transport of infective viral particles, leading to classic neurological sequelae associated with disease progression [15–17]. Due to the efficient neuroinvasive properties of RABV [18,19], including the ability to bypass the blood-brain barrier, studies have used RABV-based vectors for the delivery of drugs to the CNS, with some success [20]. Furthermore, genetic engineering of the RABV has been employed to generate novel vaccines consisting of non-replicating RABV particles expressing chimeric capsid proteins containing human immunodeficiency virus 1 (HIV-1) [21,22], MERS-CoV, Ebolavirus, and hepatitis C virus (HCV) sequences [23–25]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T63","span":{"begin":70,"end":71},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T64","span":{"begin":128,"end":131},"obj":"http://www.ebi.ac.uk/efo/EFO_0000302"},{"id":"T65","span":{"begin":128,"end":131},"obj":"http://www.ebi.ac.uk/efo/EFO_0000908"},{"id":"T66","span":{"begin":357,"end":362},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T67","span":{"begin":357,"end":362},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T68","span":{"begin":363,"end":368},"obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"T69","span":{"begin":363,"end":368},"obj":"http://www.ebi.ac.uk/efo/EFO_0000302"},{"id":"T70","span":{"begin":448,"end":451},"obj":"http://www.ebi.ac.uk/efo/EFO_0000302"},{"id":"T71","span":{"begin":448,"end":451},"obj":"http://www.ebi.ac.uk/efo/EFO_0000908"},{"id":"T72","span":{"begin":522,"end":525},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T73","span":{"begin":659,"end":664},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T74","span":{"begin":682,"end":687},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T75","span":{"begin":745,"end":750},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"Several empirical studies have demonstrated that the nAChR represents a major receptor for the RABV that mechanistically drives CNS transport of infective viral particles, leading to classic neurological sequelae associated with disease progression [15–17]. Due to the efficient neuroinvasive properties of RABV [18,19], including the ability to bypass the blood-brain barrier, studies have used RABV-based vectors for the delivery of drugs to the CNS, with some success [20]. Furthermore, genetic engineering of the RABV has been employed to generate novel vaccines consisting of non-replicating RABV particles expressing chimeric capsid proteins containing human immunodeficiency virus 1 (HIV-1) [21,22], MERS-CoV, Ebolavirus, and hepatitis C virus (HCV) sequences [23–25]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T12","span":{"begin":435,"end":440},"obj":"Chemical"},{"id":"T13","span":{"begin":639,"end":647},"obj":"Chemical"}],"attributes":[{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Several empirical studies have demonstrated that the nAChR represents a major receptor for the RABV that mechanistically drives CNS transport of infective viral particles, leading to classic neurological sequelae associated with disease progression [15–17]. Due to the efficient neuroinvasive properties of RABV [18,19], including the ability to bypass the blood-brain barrier, studies have used RABV-based vectors for the delivery of drugs to the CNS, with some success [20]. Furthermore, genetic engineering of the RABV has been employed to generate novel vaccines consisting of non-replicating RABV particles expressing chimeric capsid proteins containing human immunodeficiency virus 1 (HIV-1) [21,22], MERS-CoV, Ebolavirus, and hepatitis C virus (HCV) sequences [23–25]."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T20","span":{"begin":53,"end":58},"obj":"http://purl.obolibrary.org/obo/GO_0022848"},{"id":"T21","span":{"begin":132,"end":141},"obj":"http://purl.obolibrary.org/obo/GO_0006810"}],"text":"Several empirical studies have demonstrated that the nAChR represents a major receptor for the RABV that mechanistically drives CNS transport of infective viral particles, leading to classic neurological sequelae associated with disease progression [15–17]. Due to the efficient neuroinvasive properties of RABV [18,19], including the ability to bypass the blood-brain barrier, studies have used RABV-based vectors for the delivery of drugs to the CNS, with some success [20]. Furthermore, genetic engineering of the RABV has been employed to generate novel vaccines consisting of non-replicating RABV particles expressing chimeric capsid proteins containing human immunodeficiency virus 1 (HIV-1) [21,22], MERS-CoV, Ebolavirus, and hepatitis C virus (HCV) sequences [23–25]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T26","span":{"begin":0,"end":257},"obj":"Sentence"},{"id":"T27","span":{"begin":258,"end":476},"obj":"Sentence"},{"id":"T28","span":{"begin":477,"end":775},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Several empirical studies have demonstrated that the nAChR represents a major receptor for the RABV that mechanistically drives CNS transport of infective viral particles, leading to classic neurological sequelae associated with disease progression [15–17]. Due to the efficient neuroinvasive properties of RABV [18,19], including the ability to bypass the blood-brain barrier, studies have used RABV-based vectors for the delivery of drugs to the CNS, with some success [20]. Furthermore, genetic engineering of the RABV has been employed to generate novel vaccines consisting of non-replicating RABV particles expressing chimeric capsid proteins containing human immunodeficiency virus 1 (HIV-1) [21,22], MERS-CoV, Ebolavirus, and hepatitis C virus (HCV) sequences [23–25]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T8","span":{"begin":665,"end":681},"obj":"Phenotype"},{"id":"T9","span":{"begin":733,"end":742},"obj":"Phenotype"}],"attributes":[{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0002721"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0012115"}],"text":"Several empirical studies have demonstrated that the nAChR represents a major receptor for the RABV that mechanistically drives CNS transport of infective viral particles, leading to classic neurological sequelae associated with disease progression [15–17]. Due to the efficient neuroinvasive properties of RABV [18,19], including the ability to bypass the blood-brain barrier, studies have used RABV-based vectors for the delivery of drugs to the CNS, with some success [20]. Furthermore, genetic engineering of the RABV has been employed to generate novel vaccines consisting of non-replicating RABV particles expressing chimeric capsid proteins containing human immunodeficiency virus 1 (HIV-1) [21,22], MERS-CoV, Ebolavirus, and hepatitis C virus (HCV) sequences [23–25]."}

{"project":"2_test","denotations":[{"id":"32463026-3448605-69142632","span":{"begin":250,"end":252},"obj":"3448605"},{"id":"32463026-8887475-69142632","span":{"begin":250,"end":252},"obj":"8887475"},{"id":"32463026-30772332-69142632","span":{"begin":250,"end":252},"obj":"30772332"},{"id":"32463026-19946287-69142633","span":{"begin":313,"end":315},"obj":"19946287"},{"id":"32463026-23602163-69142634","span":{"begin":316,"end":318},"obj":"23602163"},{"id":"32463026-27581650-69142635","span":{"begin":472,"end":474},"obj":"27581650"},{"id":"32463026-10706640-69142636","span":{"begin":699,"end":701},"obj":"10706640"},{"id":"32463026-14610200-69142637","span":{"begin":702,"end":704},"obj":"14610200"},{"id":"32463026-26063224-69142638","span":{"begin":768,"end":770},"obj":"26063224"},{"id":"32463026-11878905-69142638","span":{"begin":768,"end":770},"obj":"11878905"}],"text":"Several empirical studies have demonstrated that the nAChR represents a major receptor for the RABV that mechanistically drives CNS transport of infective viral particles, leading to classic neurological sequelae associated with disease progression [15–17]. Due to the efficient neuroinvasive properties of RABV [18,19], including the ability to bypass the blood-brain barrier, studies have used RABV-based vectors for the delivery of drugs to the CNS, with some success [20]. Furthermore, genetic engineering of the RABV has been employed to generate novel vaccines consisting of non-replicating RABV particles expressing chimeric capsid proteins containing human immunodeficiency virus 1 (HIV-1) [21,22], MERS-CoV, Ebolavirus, and hepatitis C virus (HCV) sequences [23–25]."}